CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers

被引:39
|
作者
Jin, Chuan [1 ]
Ma, Jing [1 ]
Ramachandran, Mohanraj [1 ]
Yu, Di [1 ]
Essand, Magnus [1 ]
机构
[1] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden
基金
瑞典研究理事会;
关键词
NEUTROPHIL-ACTIVATING PROTEIN; CHIMERIC ANTIGEN RECEPTOR; IMMUNOTHERAPY; INFILTRATION; LYMPHOCYTES; EFFICACY; SURVIVAL; THERAPY;
D O I
10.1038/s41551-022-00875-5
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Chimeric antigen receptor T cells (CAR T cells) are effective against haematologic malignancies. However, in solid tumours, their potency is hampered by local immunosuppression and by the heterogeneous expression of the antigen that the CAR targets. Here we show that CAR T cells expressing a pluripotent pro-inflammatory neutrophil-activating protein (NAP) from Helicobacter pylori trigger endogenous bystander T-cell responses against solid cancers. In mice with subcutaneous murine pancreatic ductal adenocarcinomas, neuroblastomas or colon carcinomas, CAR(NAP) T cells led to slower tumour growth and higher survival rates than conventional mouse CAR T cells, regardless of target antigen, tumour type and host haplotype. In tumours with heterogeneous antigen expression, NAP secretion induced the formation of an immunologically 'hot' microenvironment that supported dendritic cell maturation and bystander responses, as indicated by epitope spreading and infiltration of cytotoxic CD8(+) T cells targeting tumour-associated antigens other than the CAR-targeted antigen. CAR T cells armed with NAP neither increased off-tumour toxicity nor hampered the efficacy of CAR T cells, and hence may have advantageous translational potential. T cells expressing a pluripotent pro-inflammatory neutrophil-activating protein from Helicobacter pylori trigger endogenous bystander T-cell responses against solid cancers.
引用
收藏
页码:830 / 841
页数:25
相关论文
共 50 条
  • [31] T Cells Expressing a Modified FcgRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors
    Rasoulouniriana, Diana
    Santana-Magal, Nadine
    Gutwillig, Amit
    Farhat-Younis, Leen
    Tal, Lior
    Amar, Sarah
    Milyavsky, Michael
    Muddineni, Siva Sai Naga Anurag
    Muddineni, Anurag
    Solomon, Neta
    Shpilt, Hana
    Dotan, Shahar
    Pilpel, Noam
    Waskow, Claudia
    Feinmesser, Meora
    Rider, Peleg
    Carmi, Yaron
    CANCER IMMUNOLOGY RESEARCH, 2023, 11 (06) : 792 - 809
  • [32] B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors
    Zhang, Zongliang
    Jiang, Caiying
    Liu, Zhiyong
    Yang, Meijia
    Tang, Xin
    Wang, Yuelong
    Zheng, Meijun
    Huang, Jianhan
    Zhong, Kunhong
    Zhao, Shasha
    Tang, Mei
    Zhou, Tingyue
    Yang, Hui
    Guo, Gang
    Zhou, Liangxue
    Xu, Jianguo
    Tong, Aiping
    MOLECULAR THERAPY-ONCOLYTICS, 2020, 17 : 180 - 189
  • [33] Fully Human B7-H3 CAR T Cells Exhibit Potent Preclinical Activity Against Solid Tumors
    Bajgain, Pradip
    MOLECULAR THERAPY, 2024, 32 (04) : 402 - 402
  • [34] IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
    Landoni, Elisa
    Woodcock, Mark G.
    Barragan, Gabriel
    Casirati, Gabriele
    Cinella, Vincenzo
    Stucchi, Simone
    Flick, Leah M.
    Withers, Tracy A.
    Hudson, Hanna
    Casorati, Giulia
    Dellabona, Paolo
    Genovese, Pietro
    Savoldo, Barbara
    Metelitsa, Leonid S.
    Dotti, Gianpietro
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [35] CAR-T cells to deliver engineered peptide antigens and reprogram antigen specific T cell responses against solid tumors.
    Lee, Daniel
    Minn, Andy J.
    Johnson, Lexus R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors
    Parihar, Robin
    Rivas, Charlotte
    Mai Huynh
    Omer, Bilal
    Lapteva, Natalia
    Metelitsa, Leonid S.
    Gottschalk, Stephen M.
    Rooney, Cliona M.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (03) : 363 - 375
  • [37] Allogeneic CRISPR engineered anti CD70 CAR T cells demonstrate potent preclinical activity against both solid and hematological cancer cells
    Padalia, Zinkal
    Porras, Ashley
    Dequeant, Mary Lee
    Sagert, Jason
    Thao Nguyen
    John, Matthias
    Allen, Melanie
    Dar, Henia
    Henderson, Daniel
    Police, Seshidar
    Mu, Dakai
    Maeng, Kelly
    Huang, Elaine
    Spencer, Sarah
    Lorson, Nickolaus
    Gonzales, Paul
    Holmquist, Chelsea
    Hirschfeld, Gregg
    Terrett, Jonathan A.
    Kalaitzidis, Demetrios
    CANCER RESEARCH, 2018, 78 (13)
  • [38] hYP218 CAR-T cells targeting a membrane-proximal epitope of mesothelin are highly effective against mesothelin expressing cancers.
    Tomar, Sakshi
    Zhang, Jingli
    Li, Nan
    Pastan, Ira
    Ho, Mitchell
    Hassan, Raffit
    CANCER RESEARCH, 2022, 82 (12)
  • [39] Murine T Cells Modified with FVIII CAR and Foxp3 Alleviate Anti-Factor VIII Immune Responses
    Fu, Richard Y.
    Lyle, Meghan J.
    Cai, Xiaohe
    Khan, Iram
    Rawlings, David J.
    Miao, Carol H.
    MOLECULAR THERAPY, 2018, 26 (05) : 377 - 377
  • [40] Engineering CAR T cells with a GM-CSF:IL-18 cytokine switch receptor results in potent antitumor activity in solid tumors
    Lange, Shannon Marie
    Sand, Laurens
    Gottschalk, Stephen
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):